Thienopyridine
Thienopyridines are a class of selective, irreversible[1] ADP receptor/P2Y12 inhibitors used for their anti-platelet activity. They have a significant role in the management of cardiovascular disease.
Clinical Uses
[edit]They are used in the management of peripheral artery disease, as well as the prevention of coronary stent thrombosis and strokes.
Examples
[edit]Drugs in this class include: clopidogrel (Plavix),[2] prasugrel (Effient),[3] and ticlopidine (Ticlid).
Tinoridine was actually a predecessor to this work.
Alternatives
[edit]Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that is distinct from the mechanism of the thienopyridines in that it reversibly (rather than irreversibly) inhibits the P2Y12 receptor.[1]
References
[edit]- ^ a b Alexopoulos, Dimitrios (2014). "P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa". Cardiology. 127 (4): 211–219. doi:10.1159/000357399. PMID 24458006.
- ^ Depta, Jeremiah P.; Bhatt, Deepak L. (2008-01-01). "Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance". American Journal of Cardiovascular Drugs. 8 (2): 91–112. doi:10.1007/BF03256587. ISSN 1175-3277. PMID 18422393. S2CID 34689805.
- ^ Angiolillo DJ, Bates ER, Bass TA (August 2008). "Clinical profile of prasugrel, a novel thienopyridine". Am. Heart J. 156 (2 Suppl): S16–22. doi:10.1016/j.ahj.2008.06.005. PMID 18657682.